Latest Pharmaceutical Distribution News

Page 2 of 3
EBOS Group Limited has reported a 7% decline in revenue and a 21% drop in net profit for FY2025, yet it maintains its final dividend at 61.5 NZ cents per share. The results reflect ongoing cost pressures and restructuring expenses amid a challenging market environment.
Ada Torres
Ada Torres
27 Aug 2025
Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.
Ada Torres
Ada Torres
19 Aug 2025
Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.
Ada Torres
Ada Torres
15 July 2025
Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.
Ada Torres
Ada Torres
15 May 2025
Sigma Healthcare’s recent merger with Chemist Warehouse Group is delivering strong earnings growth, with Normalised EBIT rising 36% in the first half of FY25. Transaction costs remain significant but the combined group’s outlook appears robust.
Ada Torres
Ada Torres
6 May 2025
Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.
Ada Torres
Ada Torres
29 Apr 2025
BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.
Ada Torres
Ada Torres
10 Feb 2025
Sigma Healthcare has raised its FY25 normalised EBIT guidance to $64-$70 million, driven by robust operational performance and the successful rollout of a key supply contract with Chemist Warehouse.
Ada Torres
Ada Torres
7 Feb 2025
Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.
Ada Torres
Ada Torres
31 Jan 2025
Sigma Healthcare has achieved unanimous shareholder approval for its proposed merger with Chemist Warehouse, marking a pivotal step toward reshaping Australia's pharmaceutical retail landscape. The merger now awaits final court approval, with implementation anticipated in mid-February 2025.
Ada Torres
Ada Torres
29 Jan 2025
Sigma Healthcare has successfully passed all key resolutions at its extraordinary general meeting, clearing a major hurdle for its proposed merger with Chemist Warehouse. The deal now awaits final court approval, with implementation expected in February.
Ada Torres
Ada Torres
29 Jan 2025
Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.
Ada Torres
Ada Torres
23 Jan 2025